IMCAS Academy International
Program

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Pfizer, Genzyme/Sanofi, Stiefel/GSK, Celgene, Aclaris Therapeutics, Dermira, Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics, Dermavant, Tevido BioDevices, EMD Serono Consultant – Pfizer, Abbvie, Genzyme/Sanofi, Aclaris Therapeutics, Janssen, TeVido BioDevices, EMD Serono, Rheos Medicines, Sun Pharmaceuticals, NIRA Biosciences, Vimela Therapeutics, KliRNA Therapeutics, Dermavant, Temprian Therapeutics, Almirall, Boston Pharma, Cogen Therapeutics, Admirx, Avita, Incyte Corp, LEO Pharma, 3rd Rock Ventures Equity – TeVido Biodevices, Rheos Medicines, Incyte Corp (auremolimab), NIRA Biosciences, Aldena Therapeutics, Vimela Therapeutics, KliRNA Therapeutics Founder – Villaris Therapeutics, Inc, NIRA Biosciences, Aldena Therapeutics, Vimela Therapeutics, KliRNA Therapeutics

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: In this lecture, we aim to explore the potential of teledermatology in enhancing accessibility to dermatology care. Our primary objective is to highlight the practical advantages of store and forward teledermatology, emphasizing its impact on improving the diagnosis and management of skin conditions. By presenting a real-life case of vitiligo, we intend to illustrate how this innovative approach can benefit patients and healthcare providers alike, ultimately leading to improved healthcare outcomes and increased access to dermatological services.

Introduction: Access to dermatology care remains a significant challenge in many regions due to factors such as geographical barriers, long wait times, and a shortage of dermatologists. Teledermatology, specifically the store and forward method, offers a promising solution to address these issues. This lecture introduces the concept of teledermatology and its various modalities, emphasizing the convenience, cost-effectiveness, and potential to reach underserved populations. Furthermore, it sets the stage for a compelling case study focusing on a patient with vitiligo.

Materials / method: The patient's medical history, clinical photographs, and relevant data were collected and transmitted to a remote dermatologist, who provided a diagnosis and treatment plan. This teledermatology approach allows for asynchronous consultation, bypassing the need for in-person appointments and reducing waiting times for specialized care.

Results: The presentation will showcase the results of the vitiligo case study, emphasizing the successful diagnosis and treatment facilitated through store and forward teledermatology. We will discuss the patient's experience, including the convenience of remote consultations and the timely delivery of care. Furthermore, we will highlight the broader implications of this case in the context of improving access to dermatology care for a diverse range of skin conditions. The lecture will conclude with a discussion of the wider implications of teledermatology in expanding access to dermatological service

Conclusion: As we conclude, it is clear that teledermatology is not only a game-changer for dermatology care but also a model for the future of healthcare accessibility. The success of this approach in improving patient outcomes, reducing healthcare costs, and increasing access to specialized care should inspire healthcare systems to further embrace telemedicine solutions.

However, it is essential to acknowledge that while store and forward teledermatology offers many advantages, it is not a one-size-fits-all solution. Challenges such as patient privacy, technology limitations, and the need for appropria

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Founder of FORMEL Skin

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability